arrow_back Back Filing freshness 10-Q FY 2026 SEC EDGAR

BIOMERICA INC

BMRA
$1.68 ▼ -0.02 (-1.18%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
17 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
12
Health
Poor
Bearish
auto_awesome

Analytical Summary

BIOMERICA INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.9M
Dividend Yield —
Revenue Growth -16.2% ↘
Op. Margin -119.5% ↘
ROIC -203.5% ↘
FCF / Share $-1.17 ↗
Trailing P/E —
Price / Book 2.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 4, 2026.

17-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.45M
↓ -16.2% —
Net Income Profit after all expenses
$-3.77M
↑ +24.1% —
Operating Margin Operating profit as % of sales
-119.5%
↓ -23.5% 0th
FCF / Share Free cash flow per share
$-1.17
↑ +29.8% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
1
Returns ↓
4
Cash Quality ↑
59

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 17 years · 65 quarters